Skip to main content

Table 1 Baseline patient characteristics in the unmatched and propensity-matched groups

From: The effect of antithrombin added to recombinant human-soluble thrombomodulin for severe community-acquired pneumonia-associated disseminated intravascular coagulation: a retrospective cohort study using a nationwide inpatient database

 Unmatched groupPropensity-matched group
rhTM+ATrhTMSMDrhTM+ATrhTMSMD
n = 253n = 409n = 189n = 189
Age, mean (SD)71.7 (13.6)73.6 (13.5)0.13471.2 (14.0)72.0 (14.2)0.057
Sex (male), n (%)86 (34.0)125 (30.6)0.07359 (31.2)60 (31.7)0.011
Hospital type (academic), n (%)100 (39.5)89 (21.8)0.39365 (34.4)62 (32.8)0.034
Hospital volume (cases/year), mean (SD)120.1 (46.5)106.4 (57.3)0.263113.1 (42.7)114.9 (57.5)0.035
ICU admission, n (%)76 (30.0)114 (27.9)0.04864 (33.9)58 (30.7)0.068
HCU admission, n (%)19 (7.5)24 (5.9)0.06615 (7.9)15 (7.9)< 0.001
Comorbidity, n (%)
 Congestive heart failure26 (10.3)57 (13.9)0.11221 (11.1)20 (10.6)0.017
 Peripheral vascular disease3 (1.2)7 (1.7)0.0443 (1.6)3 (1.6)< 0.001
 Cerebrovascular disease12 (4.7)20 (4.9)0.0079 (4.8)7 (3.7)0.053
 Dementia6 (2.4)9 (2.2)0.0114 (2.1)6 (2.1)< 0.001
 Chronic pulmonary disease13 (5.1)26 (6.4)0.05211 (5.8)12 (6.3)0.022
 Rheumatologic disease8 (3.2)10 (2.4)0.0434 (2.1)5 (2.6)0.035
 Peptic ulcer6 (2.4)10 (2.4)0.0056 (3.2)5 (2.6)0.031
 Mild liver disease9 (3.6)15 (3.7)0.0066 (3.2)7 (3.7)0.029
 Diabetes without chronic complications27 (10.7)43 (10.5)0.00521 (11.1)20 (10.6)0.017
 Diabetes with chronic complications8 (3.2)14 (3.4)0.0158 (4.2)8 (4.2)< 0.001
 Renal disease20 (7.9)28 (6.8)0.04117 (9.0)15 (7.9)0.038
Consciousness level, n (%)      
 Alert80 (31.6)192 (46.9)0.31873 (38.6)68 (36.0)0.055
 Delirium71 (28.1)83 (20.3)0.18249 (25.9)53 (28.0)0.048
 Somnolence47 (18.6)47 (11.5)0.19926 (13.8)24 (12.7)0.031
 Coma52 (20.6)70 (17.1)0.08838 (20.1)40 (21.2)0.026
Intervention, n (%)
 Mechanical ventilation203 (80.2)268 (65.5)0.336144 (76.2)141 (74.6)0.037
 Intermittent renal replacement therapy62 (24.5)53 (13.0)0.29937 (19.6)41 (21.7)0.052
 Continuous renal replacement therapy10 (4.0)11 (2.7)0.0717 (3.7)6 (3.2)0.029
 Polymyxin B hemoperfusion43 (17.0)39 (9.5)0.22124 (12.7)27 (14.3)0.046
 Bacterial culture collection244 (96.4)382 (93.4)0.139180 (95.2)179 (94.7)0.024
 Bronchoscopy20 (7.9)16 (3.9)0.1712 (6.3)12 (6.3)< 0.001
Catecholamine, n (%)
 Noradrenaline199 (78.7)232 (56.7)0.482139 (73.5)138 (73.0)0.012
 Dopamine99 (39.1)213 (52.1)0.26280 (42.3)84 (44.4)0.043
Platelet transfusion, n (%)30 (11.9)32 (7.8)0.13620 (10.6)18 (9.5)0.035
Fresh-frozen plasma transfusion, n (%)28 (11.1)15 (3.7)0.28610 (5.3)14 (7.4)0.087
Immunoglobulin, n (%)136 (53.8)125 (30.6)0.48391 (48.1)85 (45.0)0.064
Heparin, n (%)209 (82.6)242 (59.2)0.534148 (78.3)152 (80.4)0.052
Danaparoid, n (%)5 (2.0)8 (2.0)0.0015 (2.6)4 (2.1)0.035
Sivelestat sodium, n (%)81 (32.0)101 (24.7)0.16361 (32.3)62 (32.8)0.011
Low-molecular-weight heparin, n (%)7 (2.8)7 (1.7)0.0716 (3.2)5 (2.6)0.031
Hydrocortisone, n (%)73 (28.9)82 (20.0)0.20644 (23.3)52 (27.5)0.097
Initial antibiotic use, n (%)
 Ampicillin5 (2.0)5 (1.2)0.064 (2.1)2 (1.1)0.085
 Ampicillin/sulbactam29 (11.5)52 (12.7)0.03825 (13.2)26 (13.8)0.015
 Piperacillin/tazobactam48 (19.0)76 (18.6)0.0137 (19.6)37 (19.6)< 0.001
 First-generation cephalosporin3 (1.2)2 (0.5)0.0772 (1.1)2 (1.1)< 0.001
 Third-generation cephalosporin without effect for Pseudomonas aeruginosa38 (15.0)55 (13.4)0.04530 (15.9)24 (12.7)0.091
 Fourth-generation cephalosporin6 (2.4)14 (3.4)0.0635 (2.6)4 (2.1)0.035
 Carbapenem164 (64.8)262 (64.1)0.016119 (63.0)116 (61.4)0.033
 Aminoglycoside5 (2.0)5 (1.2)0.064 (2.1)2 (1.1)0.085
 Fluoroquinolone68 (26.9)103 (25.2)0.03949 (25.9)54 (28.6)0.059
 Macrolide43 (17.0)54 (13.2)0.10630 (15.9)24 (12.7)0.044
 Tetracycline7 (2.8)30 (7.3)0.217 (3.7)5 (2.6)0.06
 Clindamycin12 (4.7)20 (4.9)0.0078 (4.2)11 (5.8)0.073
 Anti-MRSA drug43 (17.0)44 (10.8)0.18123 (12.2)22 (11.6)0.016
 Antifungal drug5 (2.0)5 (1.2)0.064 (2.1)4 (2.1)< 0.001
  1. Abbreviations: rhTM recombinant human-soluble thrombomodulin, AT antithrombin, SMD standardized mean difference, SD standard deviation, ICU intensive care unit, HCU high care unit, MRSA methicillin-resistant Staphylococcus aureus